-
verification and assurance options, Specifically, the role will involve investigating: Excessive Agency and discovery of data and other misconfigured attack vectors an AI system can exploit. Misuse, by analysing
-
Project: Novel GM interventions for mosquito control could represent a step change in progressing towards elimination of the world’s most harmful vector-borne diseases, including malaria and dengue. However
-
looking at the design and analysis of randomised trials of interventions to reduce the risk of vector-borne diseases (e.g. malaria and dengue). The Project offers an interdisciplinary opportunity to work in
-
of schistosomiasis across rural-to-urban settings and develop tools to support targeted interventions. A key focus will be on mapping snail vector distribution near expanding water infrastructure (e.g., sand dams) in
-
methodology project looking at the design and analysis of randomised trials of interventions to reduce the risk of vector-borne diseases (e.g. malaria and dengue). The Project offers an interdisciplinary
-
transmission risk. This will include investigating the distribution and abundance of snail vectors of schistosomiasis along the increasing number of water management infrastructure (e.g. sand dams) in Kenya, and
-
mosquito vector. This is to dissect the protein network and how key novel signalling proteins are involved parasite proliferation stages. The work will involves gene targeting both conditional knockdown and
-
mosquito vector. This is to dissect the protein network and how key novel signalling proteins are involved parasite proliferation stages. The work will involves gene targeting both conditional knockdown and
-
viral (AAV) vectors. We propose to compare the capabilities of this instrument with that of commercially available mass spectrometry platforms and other methods. As part of this exciting and truly
-
translated eleven vaccine candidates, including viral vectors, recombinant proteins-in-adjuvants and a virus-like particle, into Phase 1 and 2 clinical trials in the UK and Africa. Over half of these trials